Editas Medicine, Inc. Board of Directors

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Dr. Gilmore O'Neill M.D.

Dr. Gilmore O'Neill M.D.

President, CEO & Director

Ms. Linea Aspesi

Ms. Linea Aspesi

Executive VP & Chief People Officer

Dr. George McDonald Church Ph.D.

Dr. George McDonald Church Ph.D.

Co-Founder & Scientific Advisory Board Member

Cristi Barnett

Cristi Barnett

Senior VP of Corporate Communications & Investor Relations

Dr. Linda C. Burkly Ph.D.

Dr. Linda C. Burkly Ph.D.

Executive VP & Chief Scientific Officer

Mr. Gregory Whitehead

Mr. Gregory Whitehead

Executive VP and Chief Technical & Quality Officer

Ms. Caren Deardorf

Ms. Caren Deardorf

Executive VP and Chief Commercial & Strategy Officer

Dr. Feng Zhang Ph.D.

Dr. Feng Zhang Ph.D.

Co-Founder & Scientific Advisory Board Member

Ms. Charlene Stern J.D., Ph.D.

Ms. Charlene Stern J.D., Ph.D.

Executive VP & General Counsel

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.